Analysts See $-0.51 EPS for KalVista Pharmaceuticals, Inc. (KALV)

November 11, 2018 - By Mona Holcomb

Analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to report $-0.51 EPS on December, 13.They anticipate $0.01 EPS change or 2.00 % from last quarter’s $-0.5 EPS. After having $-0.47 EPS previously, KalVista Pharmaceuticals, Inc.’s analysts see 8.51 % EPS growth. The stock decreased 0.79% or $0.15 during the last trading session, reaching $18.82. About 25,566 shares traded. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has risen 81.98% since November 11, 2017 and is uptrending. It has outperformed by 66.36% the S&P500.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company has market cap of $323.32 million. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. It currently has negative earnings. The Company’s products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein.

More important recent KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For October 30, 2018” on October 30, 2018, also Nasdaq.com published article titled: “Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive …”, Seekingalpha.com published: “Premarket analyst action – healthcare” on October 15, 2018. More interesting news about KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was released by: Streetinsider.com and their article: “Stifel Starts Kalvista Pharmaceuticals Inc (KALV) at Buy” with publication date: October 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: